AGEN Agenus Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AGEN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$3.06
Analyst Target
$12.33
+303.0%
Upside
52W High
$7.34
52W Low
$1.38
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 21, 2026
Market cap
$110.59M
P/E
N/A
ROE
N/A
Profit margin
-32.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
AGEN's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score underscores critical bankruptcy risk. Despite a 20.4% YoY revenue growth, the company operates at a deep loss with a -32.92% profit margin, negative ROA (-16.66%), and a dangerously low current ratio of 0.47. The stock trades at a price-to-sales of 1.04 but has no intrinsic value or Graham Number, suggesting valuation is driven purely by speculative growth expectations. Analysts' target price of $12.33 appears disconnected from fundamentals, and insider activity remains neutral with no recent buying activity.
Key Strengths
20.4% year-over-year revenue growth indicates top-line expansion in a competitive biotech sector
Recent quarterly earnings show some improvement in EPS surprise (e.g., +48% in Q1 2025)
Positive Q/Q EPS growth of +62.3% suggests potential earnings recovery momentum
Market cap of $0.11B places it in a small-cap biotech niche with high volatility and upside potential
Analyst target price of $12.33 implies strong upside potential if fundamentals improve
Key Risks
Piotroski F-Score of 0/9 signals extreme financial distress and operational failure
Negative ROA (-16.66%) and negative ROIC indicate inefficient capital use
Current ratio of 0.47 and quick ratio of 0.03 suggest severe liquidity risk and inability to meet short-term obligations
Profit margin of -32.92% and gross margin of just 0.08% reflect deep operational inefficiencies
No free cash flow, operating cash flow, or dividend history; high reliance on external financing
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
23
Weak
30
55
20
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 0/9, Negative ROA and ROIC, Liquidity ratios below 1.0, Negative profitability across all margins, No analyst consensus or target mean
Confidence
90%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 1.04 is below sector average (avg 1.04 is not available, but peers range from 0.5–2.0)
- Forward P/E of 1.57 suggests potential undervaluation if earnings turn positive
Watchpoints
- No Graham Number or intrinsic value due to negative earnings and lack of stable cash flows
- Price-to-book of -0.37 indicates negative book value, implying insolvency risk
- Valuation is speculative and not supported by fundamentals
Future
55/100
Ref Growth rates
Positives
- 20.4% YoY revenue growth shows top-line momentum
- Recent improvement in EPS surprise (e.g., +48% in Q1 2025)
- Positive Q/Q EPS growth of +62.3% suggests earnings recovery
Watchpoints
- Forward P/E of 1.57 is misleading without sustainable earnings
- No free cash flow or operating cash flow data
- High volatility and lack of earnings consistency
Past
20/100
Ref Historical trends
Positives
- Historical revenue growth has been positive in recent quarters
- Some quarters have shown better-than-expected EPS (e.g., Q1 2025)
Watchpoints
- Persistent negative earnings across 25 quarters
- Average earnings surprise of -92.94% over last 4 quarters
- Most recent quarter missed estimates by 152.9%
- Negative EPS trend over 2+ years
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Revenue growth indicates business activity
Watchpoints
- Piotroski F-Score of 0/9 indicates complete financial deterioration
- No Altman Z-Score available, but liquidity ratios (current: 0.47, quick: 0.03) suggest distress
- Negative ROA and ROIC indicate poor capital efficiency
- No cash flow data suggests inability to generate internal funds
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength of 0/100 confirms no dividend policy
- Company is not financially stable enough to pay dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.06
Analyst Target
$12.33
Upside/Downside
+303.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AGEN and closest competitors.
Updated 2026-02-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AGEN
Agenus Inc.
Primary
|
-96.4% | -92.5% | -11.3% | -32.3% | -10.0% | +4.8% |
|
ANL
Adlai Nortye Ltd.
Peer
|
-82.5% | -82.5% | +28.3% | +82.6% | +71.9% | +46.1% |
|
BDSX
Biodesix, Inc.
Peer
|
-97.8% | -75.2% | -34.9% | +31.6% | +72.1% | +49.0% |
|
AMWL
American Well Corporation
Peer
|
-99.3% | -93.4% | -55.6% | -45.6% | +6.1% | +3.4% |
|
ASRT
Assertio Holdings, Inc.
Peer
|
-72.2% | -81.8% | -5.3% | +3.7% | +16.3% | +0.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
1.57
PEG Ratio
N/A
P/B Ratio
-0.37
P/S Ratio
1.04
EV/Revenue
1.36
EV/EBITDA
-2.89
Market Cap
$110.59M
Profitability
Profit margins and return metrics
Profit Margin
-32.92%
Operating Margin
-16.08%
Gross Margin
0.08%
ROE
N/A
ROA
-16.66%
Growth
Revenue and earnings growth rates
Revenue Growth
+20.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.47
Weak
Quick Ratio
0.03
Poor
Cash/Share
$0.1
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-10
$N/A
2025-11-10
$-1.16
-152.9% surprise
2025-08-11
$-1.0
-173.9% surprise
2025-05-12
$-1.03
+48.0% surprise
Healthcare Sector Comparison
Comparing AGEN against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Profit Margin
-32.92%
This Stock
vs
-20.8%
Sector Avg
+58.3%
(Superior)
Revenue Growth
20.4%
This Stock
vs
62.23%
Sector Avg
-67.2%
(Slower)
Current Ratio
0.47
This Stock
vs
3.45
Sector Avg
-86.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AGEN
Agenus Inc.
|
BEARISH | $110.59M | - | -% | -32.9% | $3.06 | |
|
ANL
Adlai Nortye Ltd.
|
BEARISH | $97.05M | - | -139.0% | -% | $2.63 | |
|
BDSX
Biodesix, Inc.
|
BEARISH | $93.92M | - | -302.6% | -49.3% | $11.74 | |
|
AMWL
American Well Corporation
|
BEARISH | $79.73M | - | -37.0% | -42.8% | $4.87 | |
|
ASRT
Assertio Holdings, Inc.
|
BEARISH | $73.86M | - | -24.5% | -21.1% | $11.51 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-06 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 5,027 | $14,779 |
| 2026-01-23 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,562 | $14,781 |
| 2026-01-09 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,780 | $14,780 |
| 2026-01-02 | HARRISON THOMAS L | Director | Stock Award | 7,691 | $24,842 |
| 2025-12-26 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,942 | $16,358 |
| 2025-12-12 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,316 | $16,358 |
| 2025-11-28 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,587 | $16,357 |
| 2025-11-14 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,769 | $16,357 |
| 2025-10-31 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,120 | $16,356 |
| 2025-10-17 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,216 | $16,358 |
| 2025-10-03 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,951 | $16,357 |
| 2025-10-01 | HARRISON THOMAS L | Director | Stock Award | 5,780 | $22,542 |
| 2025-09-19 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,734 | $16,355 |
| 2025-09-05 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,778 | $16,359 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
3 analysts
HC Wainwright & Co.
2025-09-10
Buy
Buy
HC Wainwright & Co.
2025-08-28
Buy
Buy
Past News Coverage
Recent headlines mentioning AGEN from our newsroom.
Newest → oldest
No matching news yet.